Navigation Links
Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States

Provides supplemental recognition factor to assist in product


INDIANAPOLIS, Oct. 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced the introduction of a color differentiation system for U-100 insulin products marketed in the United States, including vials, pens and individual packaging for Humalog(R) (insulin lispro injection [rDNA origin]) and Humulin(R) (regular insulin human injection, USP [rDNA origin)]).

The Lilly color differentiation system - also used for Humalog and Humulin formulations marketed in Europe - follows the introduction of bar coding of packaging and insulin vials instituted in the U.S. by Lilly in 2004. Combined, these safety measures offer patients, physicians, pharmacists and other health care professionals a multi-tiered product identification and recognition system for Lilly's insulin products.

With color differentiation, the redesigned labeling can help patients, health care providers and pharmacists accurately identify the insulin that has been prescribed.

"Insulin is a powerful medicine that has an 85-year track record of efficacy and safety when administered and used properly. But if insulin is administered improperly, patients could be put at risk of serious injury because blood sugar levels may drop too low," said Sherry Martin, M.D., Associate Medical Director, Lilly USA. "Differentiating insulins with clearly printed labels and color-differentiated packaging has the potential to help reduce medication errors and improve safety for patients with diabetes. The use of color provides a supplemental recognition factor beyond the actual wording on the label. However, people should remember that color differentiation of insulin is not a substitute for reading the label carefully before using insulin."

The first device to be packaged in accordance with the new color differentiation system is Humalog(R) KwikPen(R), an insulin pen prefilled with the Humalog brand of insulins. Humalog KwikPen is designed to be convenient, easy to use and discreet, and its design can help fit a mealtime insulin, such as Humalog, into the daily lives and routines of people with diabetes. The Humalog brand of insulins is indicated for use in patients with diabetes to control high blood sugar. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Color differentiation of other Humalog and Humulin U-100 products, including vials, is being introduced throughout 2008. Colors indicate both insulin family and insulin type: burgundy for the Humalog family, blue for the Humulin family, and yellow for Regular insulin. For example, a blue-yellow combination would indicate Humulin-R. Insulin mixes will also be addressed with a two-color system. The products will be differentiated by the following colors:

Humalog (insulin lispro injection [rDNA origin]) = burgundy

Humalog Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]) = burgundy and yellow

Humalog Mix50/50 (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]) = burgundy and red
Humulin 70/30 = dark blue and brown

Humulin R = dark blue and light yellow

Humulin N = dark blue and bright green

To learn more about color differentiation and insulin delivery devices for use with the Humalog brand of insulins, visit

About the Humalog Brand of Insulins

Humalog (insulin lispro injection [rDNA origin]), Humalog Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]), and Humalog Mix50/50 (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]) are for use in patients with diabetes to control high blood sugar. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Important Safety Information

Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Humalog is an injectable, fast-acting insulin. Humalog Mix75/25 and Humalog Mix50/50 are a mixture of fast-acting and longer-acting insulins. These insulins start working faster than other insulins that contain regular human insulin. Humalog, Humalog Mix75/25, and Humalog Mix50/50 should be taken within 15 minutes before a meal. Humalog can be taken right after eating a meal. Check your blood sugar levels as told by your healthcare professional.

If you have type 1 diabetes, you need to take a longer-acting insulin in addition to Humalog (except when using an external insulin pump). If you have type 2 diabetes, you may be taking diabetes pills and/or a longer-acting insulin in addition to Humalog.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. The safety and effectiveness of Humalog Mix75/25 and Humalog Mix50/50 in patients less than 18 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog, Humalog Mix75/25, or Humalog Mix50/50 in pregnant or nursing women.

Humalog, Humalog Mix75/25, and Humalog Mix50/50 should not be used during episodes of low blood sugar (hypoglycemia) or if you are allergic to anything in these insulins.

Low Blood Sugar

Low blood sugar is the most common adverse effect associated with insulins, including Humalog, Humalog Mix75/25, and Humalog Mix50/50. Low blood sugar can happen suddenly, and symptoms may be different for each person and may change from time to time. Know your symptoms of low blood sugar. Severe low blood sugar can cause seizures and be life- threatening. Follow your healthcare professional's instructions for treating low blood sugar. Talk to your healthcare professional if low blood sugar is a problem for you.

Other Side Effects

Other potential side effects associated with the use of insulins include: low blood potassium, weight gain, changes in fat tissue at the injection site, and allergic reactions. Allergic reactions can happen at the site of injection and over the whole body. Whole body allergic reactions are less common, but may be life-threatening.

For other important information, see the accompanying Patient Information leaflet.

Please see full user manual that accompanies the Pen.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy -- practical tools, education and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at

Humalog(R) is a registered trademark of Eli Lilly and Company. Humalog(R) Mix75/25(TM) and Humalog(R) Mix50/50(TM) are trademarks of Eli Lilly and Company. Humalog(R) KwikPen(R) is a registered trademark of Eli Lilly and Company. Humulin(R) R Regular; Humulin(R) N NPH and Humulin(R) 70/30 are trademarks of Eli Lilly and Company.


(Logo: )

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):